Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Sleep Initiation and Maintenance Disorders 1 Pain, Postoperative 1 Pain 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Head and Neck Neoplasms 1 Fatigue 1 Depression 1 Carcinoma, Non-Small-Cell Lung 1 Agnosia 1

Interventions

Rituximab 344 Cyclophosphamide 317 fludarabine phosphate 142 Etoposide 139 Peripheral Blood Stem Cell Transplantation 124 fludarabine 112 Filgrastim 112 Mycophenolic Acid 98 Melphalan 98 Whole-Body Irradiation 90 Vincristine 90 Busulfan 87 Cytarabine 85 Doxorubicin 79 Cyclosporine 76 Tacrolimus 75 Radiotherapy 75 Prednisone 73 Bendamustine Hydrochloride 72 Granulocyte Colony-Stimulating Factor 66 Methotrexate 65 Antilymphocyte Serum 56 Carmustine 54 Dexamethasone 50 Gemcitabine 48 Lenalidomide 46 Bortezomib 43 venetoclax 41 ibritumomab tiuxetan 37 obinutuzumab 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Analgesics × Clear all

NCT00719472 2017-05-15

RATE

Genentech, Inc.

Phase 3 Completed

451 enrolled 11 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡